New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
07:28 EDTSHPGShire enters licensing and collaboration agreement with ArmaGen
Shire and ArmaGen, a US privately held biotechnology company, announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy for the potential treatment of both the central nervous system and somatic manifestations in patients with Hunter syndrome. Shire will obtain worldwide commercialization rights for AGT-182 in exchange for payments of approximately $225M to ArmaGen, including an initial upfront payment of $15M in cash and equity, an additional equity investment, R&D funding, development milestones and sales milestones, in addition to royalty payments. ArmaGen will be responsible for conducting and completing the Phase I/II study which it expects to initiate before the end of 2014, after which point Shire will be responsible for further clinical development, including Phase III trials, and commercialization.
News For SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
11:28 EDTSHPGNPS Pharmaceuticals calls active on Shire considering bid report
Subscribe for More Information
11:13 EDTSHPGShire considering bid for NPS Pharmaceuticals, Bloomberg reports
Subscribe for More Information
10:49 EDTSHPGNPS Pharmaceuticals jumps 12%, halted after report of potential Shire bid
Shire (SHPG) has NPS Pharmaceuticals (NPSP) on the top of its list of potential takeover targets, but is also said to be considering other targets, according to Bloomberg.
10:47 EDTSHPGNPS Pharmaceuticals said to be on top of Shire takeover list, Bloommberg says
Subscribe for More Information
10:47 EDTSHPGNPS halted for volatility after Bloomberg says Shire considers bid
Subscribe for More Information
December 11, 2014
08:57 EDTSHPGLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
06:29 EDTSHPGShire CEO sees no immediate need to spend break-up fee, Reuters reports
Subscribe for More Information
December 9, 2014
12:22 EDTSHPGPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
10:23 EDTSHPGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:38 EDTSHPGShire downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use